TB Fast Track

Conditions

HIV-associated tuberculosis Infections and Infestations Tuberculosis

Grant AD, Charalambous S, Tlali M, Karat AS, Dorman SE, Hoffmann CJ, Johnson S, Vassall A, Churchyard GJ, Fielding KL.

2019-11-1136 citations

TB Fast Track: a study to evaluate the effect of a point-of-care TB test-and-treat algorithm on early mortality in people with HIV accessing ART, a trial with randomisation at clinic level

Kathering Fielding, Salome Charalambous, Christopher J. Hoffmann, Suzanne M. Johnson, Mpho Tlali et al. (9 authors)

LSHTM Research Online (London School of Hygiene and Tropical Medicine)2019-01-011 citations

10.17037/pubs.04653158

Evaluation of a point-of-care tuberculosis test-and-treat algorithm on early mortality in people with HIV accessing antiretroviral therapy (TB Fast Track study): study protocol for a cluster randomised controlled trial

Katherine Fielding, Salome Charalambous, Christopher J. Hoffmann, Suzanne M. Johnson, Mpho Tlali et al. (9 authors)

Trials2015-03-2714 citations

10.1186/s13063-015-0650-0

Interventions

A management strategy based on a point of care technology-based algorithm to rapidly identify individuals at high risk of TB, based on urine LAM, haemoglobin and body mass index, and ensure that those

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. HIV positive 2. Eligible and willing to start ART 3. CD4 150 cells/ul or less

Exclusion criteria

Exclusion criteria: 1. Age <18 years 2. Currently on TB treatment, or completed TB treatment in the last 3 months 3. First trimester of pregnancy, or desiring pregnancy in the next 6 months 4. Contraindication to efavirenze, based on current South African ART guidelines 5. Too sick to be managed in ambulatory care

Design outcomes

Primary

Measure	Time frame
All-cause mortality at 6 months after enrolment	—

Secondary

Measure	Time frame
1. Duration of hospital admission in first 6 months after enrolment 2. Time from enrolment to ART start 3. Proportion of patients retained in care, i.e. documented to have attended clinic for HIV care at 6 months (window: 150-240 days) after enrolment 4. Study-defined serious adverse events (particularly hepatotoxicity, hypersensitivity, peripheral neuropathy, and nephrotoxicity) in the intervention arm 5. Economic outcomes	—

Measure

Time frame

1. Duration of hospital admission in first 6 months after enrolment 2. Time from enrolment to ART start 3. Proportion of patients retained in care, i.e. documented to have attended clinic for HIV care at 6 months (window: 150-240 days) after enrolment 4. Study-defined serious adverse events (particularly hepatotoxicity, hypersensitivity, peripheral neuropathy, and nephrotoxicity) in the intervention arm 5. Economic outcomes

—

Countries

South Africa

Outcome results

None listed